RENAL CELL CARCINOMA (RCC) IN YOUNG ADULTS: A CASE REPORT AND LITERATURE REVIEW
Received 2023-09-20; Accepted 2023-12-06; Published 2024-08-01
DOI:
https://doi.org/10.22452/jummec.vol27no2.3Keywords:
Pediatric renal cell carcinoma, anti-VEGF use in pediatric population, immune checkpoint inhibitors in pediatric population, precision medicine, personalized medicineAbstract
Pediatric renal cell carcinoma (RCC) is a rare disease entity and found to show significant differences from adult RCC in terms of epidemiological and histological subtypes. Treatment strategies for paediatric RCC were mainly adopted from adult RCC as there’s no internationally recognized standard treatment guideline to date. Data on clinical outcomes are scarce. We hereby report a case of a 14-year-old female diagnosed with advanced clear cell RCC treated with pazopanib with overall survival of 10 months. There are several case reports and case series supporting the use of anti-VEGF in adolescent RCC though not in clear cell RCC. None has incorporated immune checkpoint inhibitors in adolescent RCC. Safety and efficacy in dosing strategies of anti-VEGF in adolescents is another challenge. As cancer care advances, large scale genetic data analysis leads to the emergence of precision and personalized medicine, but its utilisation in pediatric RCC is yet to be addressed.
Downloads
Downloads
Published
Issue
Section
License
All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.